OrchestRA and the End of Linear Drug Discovery
Handoffs are where promising projects quietly become expensive. A biologist identifies a plausible target. A chemistry team designs a molecule that appears to bind it. Weeks later, pharmacology discovers that the molecule is poorly absorbed, rapidly cleared, or inconveniently toxic. The result travels back upstream as a report, perhaps accompanied by a meeting, several caveats, and the medicinal-chemistry equivalent of “please try again.” ...